NEW YORK (GenomeWeb) – QuantuMDx is working with partners in South America and Asia to trial the use of its platform for human papillomavirus testing in low-resource settings.

The British molecular diagnostics firm also recently completed a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year. Once a CE-IVD marking is achieved, QuantuMDx plans to obtain a separate CE-IVD certification for its HPV assay by mid-2020, according to John Burn, its founder and chairman.